Neurolutions developed the IpsiHand Upper Limb Rehabilitation System, an EEG-controlled robotic exoskeleton for post-stroke motor recovery. The IpsiHand received FDA De Novo clearance in 2021 — the first BCI-based rehabilitation device to receive this designation — and targets the approximately 800,000 Americans who suffer strokes annually. Neurolutions was subsequently acquired by CDH Bioscience. The device leverages the brain's ipsilateral (same-side) motor control pathways that remain intact after stroke to drive rehabilitation of the paralyzed hand.